Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Incidence of Ocular Inflammation as Defined by the Inflammadry Assay in 250 Consecutive Cataract Patients and Their Response to Treatment With Xiidra

Next Previous
Trial Profile

The Incidence of Ocular Inflammation as Defined by the Inflammadry Assay in 250 Consecutive Cataract Patients and Their Response to Treatment With Xiidra

Status: Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 31 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lifitegrast (Primary)
  • Indications Ocular inflammation
  • Focus Therapeutic Use

Most Recent Events

  • 25 Jul 2023 Status changed from discontinued to withdrawn prior to enrolment due to administrative reasons.
  • 31 Oct 2022 Status changed from recruiting to discontinued.
  • 28 Sep 2021 Planned End Date changed from 25 Sep 2021 to 25 Sep 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top